← Back to Search


Rivaroxaban for Deep Vein Thrombosis ((RAMBLE) Trial)

Phase 2 & 3
Waitlist Available
Led By Jeffrey A Kline, MD
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Screening 3 weeks
Treatment Varies
Follow Up 1, 2, and 3 months
Awards & highlights

(RAMBLE) Trial Summary

This trial finds that apixaban is better than rivaroxaban at reducing menstrual blood loss in women with VTE or atrial fibrillation.

Eligible Conditions
  • Deep Vein Thrombosis (DVT)
  • Menstruation

(RAMBLE) Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1, 2, and 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1, 2, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PBAC Scores
Secondary outcome measures
Hemoglobin Concentration
Number of Participants Who Crossed Over to Another Anticoagulant
Number of Participants Who Discontinued Planned Drug Administration
+5 more

(RAMBLE) Trial Design

2Treatment groups
Active Control
Group I: RivaroxabanActive Control1 Intervention
Group II: ApixabanActive Control1 Intervention

Find a Location

Who is running the clinical trial?

Indiana UniversityLead Sponsor
978 Previous Clinical Trials
983,314 Total Patients Enrolled
1 Trials studying Deep Vein Thrombosis
100 Patients Enrolled for Deep Vein Thrombosis
Jeffrey A Kline, MDPrincipal InvestigatorIndiana University
4 Previous Clinical Trials
1,333 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the main conditions that Apixaban is used to manage?

"Apixaban is a medication used to treat deep vein thrombosis, venous thromboembolism, and other conditions like cerebrovascular accident and chronic coronary artery disease."

Answered by AI

Is this an innovative research project?

"Currently, there are 92 ongoing clinical trials worldwide for Apixaban. These trials are taking place in 576 different cities across 48 countries. The first trial for Apixaban was conducted in 2015 by Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma. This trial completed its Phase 3 drug approval stage and involved 2180 patients. Since 2015, there have been 297 total studies conducted."

Answered by AI

Could you give me the total number of individuals who have chosen to enroll in this research?

"Yes, the clinical trial is still active and looking for 50 participants across 2 locations, as stated on clinicaltrials.gov. The trial was first posted on September 1st, 2016 and was last updated on December 4th, 2019."

Answered by AI

Who would be most beneficial to have as participants in this clinical trial?

"To be accepted into this trial, patients must be aged 18 to 50, have venous thromboembolism, and meet the following criteria: non-pregnant women who have active menstruation (this does not apply to women who have recently been pregnant) and must have a working telephone."

Answered by AI

Are adolescents eligible for this research study?

"From the eligibility requirements, we can see that only people aged 18 to 50 are able to participate in this trial. There are 8 other clinical trials available for patients under 18 and 159 for seniors."

Answered by AI
Recent research and studies
~2 spots leftby Apr 2025